<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005623</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067765</org_study_id>
    <secondary_id>BARR-PCA-301</secondary_id>
    <nct_id>NCT00005623</nct_id>
  </id_info>
  <brief_title>Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer</brief_title>
  <official_title>A Phase III, Randomized, Multicenter, Placebo-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of CyPat (Cyproterone Acetate [CA]) for the Treatment of Hot Flashes Following Surgical or Chemical Castration of Prostate Cancer Patients and Its Impact on the Quality of Life in These Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barr Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Cyproterone acetate may be effective treatment for hot flashes following surgical&#xD;
      or chemical castration for prostate cancer. It is not yet known which regimen of cyproterone&#xD;
      acetate is more effective for hot flashes.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to determine the effectiveness of cyproterone acetate in&#xD;
      treating patients who have hot flashes following surgical or chemical castration for prostate&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of cyproterone acetate in patients with hot flashes following&#xD;
           bilateral orchiectomy or medical castration for prostate cancer.&#xD;
&#xD;
        -  Compare the effectiveness of two doses of cyproterone acetate in these patients.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
        -  Determine the impact of this regimen on the quality of life of these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo controlled study.&#xD;
&#xD;
      Patients receive one of two doses of oral cyproterone acetate or placebo for 12 weeks,&#xD;
      followed by a 6-9 month open label extension period with all patients receiving cyproterone&#xD;
      acetate.&#xD;
&#xD;
      Quality of life is assessed.&#xD;
&#xD;
      PROJECTED ACCRUAL: Not specified&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">January 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Hot Flashes</condition>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyproterone acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Prostate cancer patients who have undergone bilateral orchiectomy or medical&#xD;
             castration (LHRH agonist drugs) and are experiencing hot flashes&#xD;
&#xD;
          -  Hot flashes are defined as:&#xD;
&#xD;
               -  At least 3 to 4 moderate to severe hot flashes per day or 21 per week at baseline&#xD;
&#xD;
               -  Present at least 1 month prior to study&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 12 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/uL&#xD;
&#xD;
          -  Platelet count at least 75,000/uL&#xD;
&#xD;
          -  Hemoglobin at least 6.2 mmol/L&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.8 mg/dL&#xD;
&#xD;
          -  SGPT no greater than 96 u/L&#xD;
&#xD;
          -  SGOT no greater than 90 u/L&#xD;
&#xD;
          -  LDH no greater than 600&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  BUN no greater than 42 mg/dL&#xD;
&#xD;
          -  Creatinine no greater than 3.39 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiovascular risks (e.g., history of angina pectoris) unless controlled by&#xD;
             medical or surgical therapy&#xD;
&#xD;
          -  No known history of thromboembolic disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Comprehend and understand English language&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years except treated squamous or basal&#xD;
             cell skin cancer or superficial bladder carcinoma&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least a 4 week washout period is required if prior antineoplastic or cytotoxic&#xD;
             chemotherapy has been used&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least a 4 week washout period is required if prior estrogens, antiandrogens (e.g.,&#xD;
             flutamide or bicalutamide), progestational agents, or corticosteroids have been used&#xD;
&#xD;
          -  No concurrent herbal medications with known hormonal ingredients (i.e.,&#xD;
             phytoestrogens)&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least a 4 week washout period is required if prior clonidine or monoamine oxidase&#xD;
             inhibitors have been used&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald W. Lewis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>MBCCOP - Medical College of Georgia Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barr Laboratories, Incorporated</name>
      <address>
        <city>Pomona</city>
        <state>New York</state>
        <zip>10970-0519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2003</verification_date>
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>hot flashes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyproterone Acetate</mesh_term>
    <mesh_term>Cyproterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

